Meeting
2017 Genitourinary Cancers Symposium
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC.
Authors
Michael Paul Kolinsky
The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
Michael Paul Kolinsky , Pasquale Rescigno , Diletta Bianchini , Zafeiris Zafeiriou , Niven Mehra , Joaquin Mateo , Ruth Riisnaes , Mateus Crespo , Ines Figueiredo , Penelope Flohr , Nina Tunariu , Udai Banerji , Florence I. Raynaud , Karen E Swales , Holly Tovey , Nuria Porta , Rachel Slade , Lorna Leonard , Emma Hall , Johann S. De Bono
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02525068
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 135)
DOI
10.1200/JCO.2017.35.6_suppl.135
Abstract #
135
Poster Bd #
E13
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastasized castration-resistant prostate cancer (mCRPC): A multicenter phase I study.
First Author: Marit Vermunt
First Author: Johann S. De Bono
Poster
2021 Genitourinary Cancers Symposium
A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
First Author: Neal D. Shore
Poster
2017 ASCO Annual Meeting
Phase I dose-escalation study of fractionated-dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).
First Author: Scott T. Tagawa